Dr. Janelle Sabo, Global Therapeutics Platform Leader at Eli Lilly & Company discusses COVID-19 monoclonal antibody treatments and how if given within 10 days of symptoms appearing can decrease the risk of hospitalization and/or disease progression in appropriate patients and having a plan of action should a high-risk individual test positive.
Jamie Milas, Vice President of Marketing at Medical Microinstruments S.p.A. (MMI), an Italian startup robotics company, discusses their robotic system for microsurgery. Combining proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies, MMI’s Symani® Surgical System enables surgeons to scale down movement to enhance microsurgical procedures while expanding the field of supermicrosurgery.
Marie E. Lamont, President and Chief Operating Officer at Inteliquet™, a leader in clinical trial matching, discusses the impact COVID has had on clinical trials and how companies have leveraged advanced technology tools to further research, improve patient recruitment, and use AI and Machine Learning to recognize behaviors and patterns to constantly improve on the data collection process overall.
Returning guest, Dr. Neal Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center discusses the importance of patient-centric treatment decision-making and the publication of an easy-to-understand summary of important clinical trial data in “Future Oncology“, a leading medical journal (Online Feb 2021).
Josh Swider, CEO of Infinite Chemical Analysis Labs discusses the anticipated expansion of the hemp and cannabis industries and the new guidelines to regulate the same. He talks about a trend called “lab shopping” where cultivators are taking samples of their product to multiple labs with questionable practices to obtain the highest potency results and how this is creating an uneven playing field for labs that are operating in compliance.
Gyula Kangiszer, President, RotChrom Technologies North America, developers of the first industrial-scale Centrifugal Partition Chromatography (CPC) technology platform, discusses the partnership with Cyclolab Cyclodextrin Research and Development Laboratory Ltd. (“Cyclolab”) aimed at developing a more efficient and cost-effective process to purify Remdesivir, a direct-acting antiviral agent approved in countries around the world to treat patients with severe cases of COVID-19.Bio
Mary Lou Ballweg, President and Executive Director of the Endometriosis Association and founder of Endometriosis Awareness Month in March discusses the endometriosis diagnosis journey, the mission behind the Alliance for Endometriosis. and the importance of encouraging open and productive conversations about endometriosis
Jakob Dahlberg, CEO and co-founder at Joint Academy discusses a research study published in “JAMA Network Open” (Feb 23, 2021) that found clinically important improvements of treating knee osteoarthritis digitally rather than the traditional treatment, making it a superior treatment option with the potential to save insurance companies and their patients the costs and risks of joint surgeries.
Dr. Samuel Lederman, obstetrician, gynecologist, and a founding member of Palm Beach Obstetrics & Gynecology, discusses the positive 12-week primary analysis topline results from the Phase 3 pivotal SKYLIGHT 1™ and SKYLIGHT 2™ clinical trials for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS), also known as hot flashes, associated with menopause.
James Sapirstein, President and CEO of AzurRX BioPharma, Inc., a developer of targeted therapies for gastrointestinal (GI) diseases, discusses the continuing need for therapeutics to treat COVID-19, how SARS-CoV-2 can remain trapped in the GI system, the “long-haul” phenomenon,and FW-1022, the drug they are developing for COVID GI infections. They anticipate a Phase 2 trial in the first half of 2021.